



## Nomination of Christophe Maréchal as interim CEO

**Liege, Belgium, 21 January 2021 – 22:00 CET** - Meeting this Thursday evening, the Board of Directors of Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, took note of the arrest warrant issued against François Fornieri in connection with duties he previously performed in a company not related to Mithra.

In accordance with the Internal Governance Code, the Board of Directors has decided to entrust the position of CEO ad interim to Mr Christophe Maréchal.

Christophe Maréchal has been Chief Financial Officer (CFO) at Mithra since the beginning of 2017. With more than 20 years of experience in international finance in the industrial, telecommunications, manufacturing and banking industries, he has strong skills in operational, financial and commercial strategy. Already involved in the day-to-day management of the company and in all its strategic and operational committees, Mr Maréchal has all the expertise required to take over the company's leadership ad interim. In order to support him in his mission, the Board of Directors will very regularly follow up on the management of the company and the evolution of its main projects. It will take the necessary decisions in consultation with the CEO ad interim.

With the appointment of Mr. Maréchal, the Board of Directors of Mithra is convinced that the continuation of the operational activities of the company will proceed in an optimal way.

\*\*\*\*\*

### For more information, please contact:

**Jean-Manuel Fontaine (IRO)** : +32 476 96 54 59- [investorrelations@mithra.com](mailto:investorrelations@mithra.com)

**Maud Vanderthommen (Press)** : +32 473 58 61 04 - [press@mithra.com](mailto:press@mithra.com)

### About Mithra

*Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. [www.mithra.com](http://www.mithra.com)*

**Important information**

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*